SLC38A2 and neoplasm: In conclusion, we propose that Slc38a2 is likely a pivotal gene that mediates the activation of Mig cDC1s after combined treatment, drives the differentiation of TTSM and TPEX cells, and thereby enhances anti‐tumor immune responses.